Error loading player: No playable sources found
Results From the Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion-Dependent Non-del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents
Date
April 6, 2024
Explore related products in the following collection:
Abstract: JNCCN23-0640 https://jnccn.org/view/journal...
Speaker
Yazan Madanat, MD
UT Southwestern Simmons Comprehensive Cancer Center
General
Related Products
Treatment Outcomes in VEXAS Syndrome in Patients with MDS: A Systematic Review
Abstract: JNCCN23-0389 https://jnccn.org/view/journal... [https://jnccn.org/view/journals/jnccn/22/2.5/article-pCLO24-054…
A Phase I Study of TAS102 Plus Talazoparib in Advanced Colorectal (CRC) and Esophagogastric (EGC) Adenocarcinomas.
Abstract: JNCCN23-0513 https://jnccn.org/view/journal... [https://jnccn.org/view/journals/jnccn/22/2.5/article-pYIA24-003…
Overall Survival (OS) Impact for NSCLC Patients with irAE and Non-irAE Hospital Admissions During First line Pembrolizumab Treatment
Abstract: JNCCN23-0529 https://jnccn.org/view/journal... [https://jnccn.org/view/journals/jnccn/22/2.5/article-pCLO24-061…
Cemiplimab Use in Advanced Cutaneous Squamous Cell Carcinoma and Non-small Cell Lung Cancer - Risk Factors Associated with Mortality
Abstract: JNCCN23-0590 https://jnccn.org/view/journal... [https://jnccn.org/view/journals/jnccn/22/2.5/article-pCLO24-066…
